Frankfurt - Delayed Quote EUR

Vicore Pharma Holding AB (publ) (6Y4.F)

0.7310

-0.0160

(-2.14%)

At close: 8:11:34 AM GMT+1

Increase of Number of Shares and Votes in Vicore Pharma

STOCKHOLM, SE / ACCESSWIRE / May 31, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 31, 2024 - Vicore Pharma Holding AB (STO: VICO) ("Vicore") announced today that the number of Vicore shares and votes has increased following the exercise ...

ACCESS Newswire 8 months ago

VICO.ST
-0.36%
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis

STOCKHOLM, SWEDEN / ACCESSWIRE / May 20, 2024 / Vicore Pharma Holding (STO:VICO) Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment. The therapy was safe and well tolerated with no treatment-related ...

ACCESS Newswire 8 months ago

VICO.ST
-0.36%
Vicore Expands and Strengthens its Board of Directors

STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin ...

ACCESS Newswire 8 months ago

VICO.ST
-0.36%
Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

STOCKHOLM, SE / ACCESSWIRE / May 7, 2024 / Vicore Pharma Holding (STO:VICO) The following resolutions were passed at the annual general meeting (the "AGM") of Vicore Pharma Holding AB (publ) on 7 May 2024. Adoption of income statement and balance ...

ACCESS Newswire 9 months ago

VICO.ST
-0.36%
Interim Report January-March 2024

STOCKHOLM, SWEDEN / ACCESSWIRE / May 3, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 3 2024- Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists ...

ACCESS Newswire 9 months ago

VICO.ST
-0.36%
Vicore to Present at Upcoming Investor Conferences

STOCKHOLM, SE / ACCESSWIRE / April 12, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, April 12, 2024 - Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), ...

ACCESS Newswire 9 months ago

VICO.ST
-0.36%
Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)

STOCKHOLM, SWEDEN / ACCESSWIRE / April 4, 2024 / Vicore Pharma Holding (STO:VICO) The shareholders of Vicore Pharma Holding AB (publ), Reg. No. 556680-3804 ("Vicore Pharma" or the "Company"), with its registered offices in Stockholm, are summoned ...

ACCESS Newswire 10 months ago

VICO.ST
-0.36%
Vicore Announces Presentations at the 2024 American Thoracic Society International Conference

STOCKHOLM, SWEDEN / ACCESSWIRE / March 28, 2024 / Vicore Pharma Holding (STO:VICO) Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPF Additional presentations ...

ACCESS Newswire 10 months ago

VICO.ST
-0.36%
Vicore Publishes the Annual Report for 2023

STOCKHOLM, SWEDEN / ACCESSWIRE / March 27, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, March 27, 2024 - Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), ...

ACCESS Newswire 10 months ago

VICO.ST
-0.36%
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis

STOCKHOLM, SE / ACCESSWIRE / March 19, 2024 / Vicore Pharma Holding (STO:VICO) AlmeeTM is the first digital therapy to address anxiety and quality of life in patients living with pulmonary fibrosis (PF). AlmeeTM has shown effectiveness in reducing ...

ACCESS Newswire 10 months ago

VICO.ST
-0.36%
Year-end Report 2023

STOCKHOLM, SWEDEN / ACCESSWIRE / February 28, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, February 28, 2024- Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor ...

ACCESS Newswire 11 months ago

VICO.ST
-0.36%

Performance Overview

Return	6Y4.F	OMX Stockholm 30 Index
YTD	+3.39%	+9.71%
1-Year	-45.61%	+15.79%
3-Year	-51.65%	+18.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vicore Pharma Holding AB (publ) (6Y4.F)

Increase of Number of Shares and Votes in Vicore Pharma

Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis

Vicore Expands and Strengthens its Board of Directors

Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

Interim Report January-March 2024

Vicore to Present at Upcoming Investor Conferences

Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)

Vicore Announces Presentations at the 2024 American Thoracic Society International Conference

Vicore Publishes the Annual Report for 2023

Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis

Year-end Report 2023

Performance Overview